Sofosbuvir
Who holds supplier records for Sofosbuvir? 7 organisations hold a current record for Sofosbuvir: an active US FDA Type II Drug Master File. A further 1 organisation has only historical (inactive) DMF filings. Recorded organisation countries for current records: India (3) and China (2); not recorded for 2.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Sofosbuvir: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/sofosbuvir
Reading the evidence
- 7 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
3 of the 5 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 3 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Sofosbuvir expires 11 Jun 2031. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (7)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Sofosbuvir. Country is the organisation's recorded country, not necessarily the manufacturing site.
- Alembic Pharmaceuticals LimitedIndia Company GMP cert on recordActive DMF 32075 · latest filing Sept 2017
- BEIJING HUIKANG BOYUAN CHEMICAL TECH CO LTDChinaActive DMF 28919 · latest filing Dec 2014
- CHANGZHOU PHARMACEUTICAL FACTORYChina Company GMP cert on recordActive DMF 32048 · latest filing Sept 2017
- FUXIN LONG RUI PHARMACEUTICAL CO LTDActive DMF 33487 · latest filing Jul 2019
- Laurus Labs LimitedIndia Company GMP cert on recordActive DMF 32068 · latest filing Nov 2017
- MATRIX PHARMACORP PRIVATE LTDIndiaActive DMF 31272 · latest filing Sept 2017
- SUZHOU RYWAY BIOTECH CO LTDActive DMF 42389 · latest filing Aug 2025
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Historical records (1)
Organisations whose Type II DMFs for Sofosbuvir are no longer active. These show a past filing, not current supply.
Show all 1 historical record
- India · Inactive DMF 31511 · filed Apr 2017
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (4 listed products contain Sofosbuvir). The latest listed patent expires 11 Jun 2031. The latest listed exclusivity ended 28 Aug 2026. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Sofosbuvir is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1259059).
Chemical identity
- IUPAC name
- propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
- Canonical SMILES
- C[C@@H](C(=O)OC(C)C)N[P@](=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3
- InChIKey
- TTZHDVOVKQGIBA-IQWMDFIBSA-N
- Synonyms
- GS-7977, GS7977, PSI-7977, Psi-7977, gs-7977, Sofosbuvir, Sofosbuvir component of epclusa, Sofosbuvir component of harvoni, Sofosbuvir component of vosevi, Sovaldi, PSI 7977, GS 7977, PSI7977
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
- Mechanism of action
- RNA Replicase Inhibitors
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Sofosbuvir?
7 organisations hold an active US FDA Type II Drug Master File or a CEP for Sofosbuvir: Alembic Pharmaceuticals Limited (India), BEIJING HUIKANG BOYUAN CHEMICAL TECH CO LTD (China), CHANGZHOU PHARMACEUTICAL FACTORY (China), FUXIN LONG RUI PHARMACEUTICAL CO LTD, Laurus Labs Limited (India), MATRIX PHARMACORP PRIVATE LTD (India) and SUZHOU RYWAY BIOTECH CO LTD. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Sofosbuvir Drug Master Files are active?
Alembic Pharmaceuticals Limited (DMF 32075), BEIJING HUIKANG BOYUAN CHEMICAL TECH CO LTD (DMF 28919), CHANGZHOU PHARMACEUTICAL FACTORY (DMF 32048), FUXIN LONG RUI PHARMACEUTICAL CO LTD (DMF 33487), Laurus Labs Limited (DMF 32068), MATRIX PHARMACORP PRIVATE LTD (DMF 31272) and SUZHOU RYWAY BIOTECH CO LTD (DMF 42389). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Sofosbuvir records mean?
1 organisation has only inactive Type II DMFs for Sofosbuvir. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does the FDA Orange Book list patents for products containing Sofosbuvir?
Yes. The latest patent listed for an approved US product containing Sofosbuvir expires 11 Jun 2031, across 4 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Sofosbuvir supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Sofosbuvir?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.